Compare BMHL & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | RANI |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 106.9M |
| IPO Year | N/A | 2021 |
| Metric | BMHL | RANI |
|---|---|---|
| Price | $5.74 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 19.5K | ★ 895.2K |
| Earning Date | 06-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $2.72 | $0.39 |
| 52 Week High | $6.35 | $3.87 |
| Indicator | BMHL | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 39.50 |
| Support Level | $3.24 | $0.70 |
| Resistance Level | N/A | $1.05 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 84.21 | 25.13 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.